Bartlett & Co’s Quest Diagnostics DGX Stock Holding History

Bartlett & Co’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$15K	Hold	109	–	–	﹤0.01%	927
2023 Q3	$13K	Sell	109 -200	-65%	-$26.6K	﹤0.01%	894
2023 Q2	$43K	Hold	309	–	–	﹤0.01%	694
2023 Q1	$44K	Hold	309	–	–	﹤0.01%	586
2022 Q4	$48K	Hold	309	–	–	﹤0.01%	586
2022 Q3	$38K	Sell	309 -10	-3%	-$1.32K	﹤0.01%	606
2022 Q2	$42K	Buy	319 +10	+3%	+$1.36K	﹤0.01%	597
2022 Q1	$42K	Buy	+309	New	+$43.1K	﹤0.01%	611
2021 Q4	–	Sell	-409	Closed	-$59K	–	512
2021 Q3	$59K	Sell	409 -6	-1%	-$878	﹤0.01%	484
2021 Q2	$55K	Hold	415	–	–	﹤0.01%	493
2021 Q1	$53K	Sell	415 -200	-33%	-$24.6K	﹤0.01%	525
2020 Q4	$73K	Buy	615 +6	+1%	+$731	﹤0.01%	473
2020 Q3	$70K	Hold	609	–	–	﹤0.01%	441
2020 Q2	$69K	Hold	609	–	–	﹤0.01%	436
2020 Q1	$49K	Buy	+609	New	+$63K	﹤0.01%	461
2019 Q3	$12K	Buy	+109	New	+$11.2K	﹤0.01%	712

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bartlett & Co's DGX Position: Q4 2023 in Review

Bartlett & Co held its Quest Diagnostics (DGX) position steady in Q4 2023 at 109 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #927.

Bartlett & Co first reported a position in DGX in Q3 2019 and has held it in 16 quarters since. The position peaked at $73K in Q4 2020. 826 funds tracked by Wall St. Rank hold DGX as of Q4 2023.

Bartlett & Co held 109 shares of Quest Diagnostics worth $15K as of Q4 2023.
Bartlett & Co left its Quest Diagnostics share count unchanged in Q4 2023.
Quest Diagnostics made up ﹤0.01% of Bartlett & Co's portfolio in Q4 2023, its #927 holding.
Bartlett & Co first reported a position in Quest Diagnostics in Q3 2019 and has held it in 16 quarters since.
Bartlett & Co's Quest Diagnostics position peaked at $73K in Q4 2020.
826 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2023.

Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.